Literature DB >> 30740857

The endothelial lectin clearance receptor CLEC4M binds and internalizes factor VIII in a VWF-dependent and independent manner.

Laura L Swystun1, Colleen Notley1, Ilinca Georgescu1, Jesse D Lai1, Kate Nesbitt1, Paula D James2, David Lillicrap1.   

Abstract

Essentials CLEC4M is an endocytic receptor for factor FVIII. CLEC4M interacts with FVIII in a VWF-dependent and independent manner. CLEC4M binds to mannose-containing glycans on FVIII. CLEC4M internalization of FVIII involves clathrin coated pits.
SUMMARY: Background von Willebrand factor (VWF) and factor VIII (FVIII) circulate in the plasma as a non-covalent complex, and the majority of FVIII is likely to be cleared by VWF-dependent pathways. Clearance of VWF-free FVIII is rapid and underlies the pathological basis of some quantitative FVIII deficiencies. The receptor pathways that regulate the clearance of VWF-bound and VWF-free FVIII are incompletely uncharacterized. The human liver-expressed endothelial lectin CLEC4M has been previously characterized as a clearance receptor for VWF, although its influence on FVIII is unknown. Objective The interaction between FVIII and CLEC4M was characterized in the presence or absence of VWF. Methods FVIII interactions with CLEC4M were evaluated by in vitro cell-based and solid phase binding assays. Interactions between FVIII and CLEC4M or liver sinusoidal endothelial cells were evaluated in vivo by immunohistochemistry. Results CLEC4M-expressing HEK 293 cells bound and internalized recombinant and plasma-derived FVIII through VWF-dependent and independent mechanisms. CLEC4M binding to recombinant FVIII was dependent on mannose-exposed N-linked glycans. CLEC4M mediated FVIII internalization via a clathrin-coated pit-dependent mechanism, resulting in transport of FVIII from early and late endosomes for catabolism by lysosomes. In vivo hepatic expression of CLEC4M after hydrodynamic liver transfer was associated with a decrease in plasma levels of endogenous murine FVIII:C in normal mice, whereas infused recombinant human FVIII was associated with sinusoidal endothelial cells in the presence or absence of VWF. Conclusions These findings suggest that CLEC4M is a novel clearance receptor that interacts with mannose-exposed glycans on FVIII in the presence or absence of VWF.
© 2019 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  Factor VIII; endocytosis; endothelial cell; glycan; lectin receptor; von Willebrand factor

Mesh:

Substances:

Year:  2019        PMID: 30740857      PMCID: PMC7083068          DOI: 10.1111/jth.14404

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  47 in total

1.  Cell surface heparan sulfate proteoglycans participate in factor VIII catabolism mediated by low density lipoprotein receptor-related protein.

Authors:  A G Sarafanov; N M Ananyeva; M Shima; E L Saenko
Journal:  J Biol Chem       Date:  2001-01-12       Impact factor: 5.157

Review 2.  Elevated factor VIII levels and risk of venous thrombosis.

Authors:  P Vince Jenkins; Orla Rawley; Owen P Smith; James S O'Donnell
Journal:  Br J Haematol       Date:  2012-04-25       Impact factor: 6.998

Review 3.  Factor VIII and von Willebrand factor--too sweet for their own good.

Authors:  P J Lenting; J N Pegon; O D Christophe; C V Denis
Journal:  Haemophilia       Date:  2010-07       Impact factor: 4.287

4.  Expression of factor VIII by murine liver sinusoidal endothelial cells.

Authors:  H Do; J F Healey; E K Waller; P Lollar
Journal:  J Biol Chem       Date:  1999-07-09       Impact factor: 5.157

5.  Effect of multimerization of human and recombinant von Willebrand factor on platelet aggregation, binding to collagen and binding of coagulation factor VIII.

Authors:  B E Fischer; G Kramer; A Mitterer; L Grillberger; M Reiter; W Mundt; F Dorner; J Eibl
Journal:  Thromb Res       Date:  1996-10-01       Impact factor: 3.944

6.  Uptake of blood coagulation factor VIII by dendritic cells is mediated via its C1 domain.

Authors:  Eszter Herczenik; Simon D van Haren; Aleksandra Wroblewska; Paul Kaijen; Maartje van den Biggelaar; Alexander B Meijer; Luisa Martinez-Pomares; Anja ten Brinke; Jan Voorberg
Journal:  J Allergy Clin Immunol       Date:  2011-10-01       Impact factor: 10.793

7.  Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism.

Authors:  E L Saenko; A V Yakhyaev; I Mikhailenko; D K Strickland; A G Sarafanov
Journal:  J Biol Chem       Date:  1999-12-31       Impact factor: 5.157

8.  A conditional knockout mouse model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII.

Authors:  Scot A Fahs; Matthew T Hille; Qizhen Shi; Hartmut Weiler; Robert R Montgomery
Journal:  Blood       Date:  2014-04-04       Impact factor: 22.113

9.  FcRn Rescues Recombinant Factor VIII Fc Fusion Protein from a VWF Independent FVIII Clearance Pathway in Mouse Hepatocytes.

Authors:  Arjan van der Flier; Zhan Liu; Siyuan Tan; Kai Chen; Douglas Drager; Tongyao Liu; Susannah Patarroyo-White; Haiyan Jiang; David R Light
Journal:  PLoS One       Date:  2015-04-23       Impact factor: 3.240

10.  Microdomains of the C-type lectin DC-SIGN are portals for virus entry into dendritic cells.

Authors:  Alessandra Cambi; Frank de Lange; Noortje M van Maarseveen; Monique Nijhuis; Ben Joosten; Erik M H P van Dijk; Bärbel I de Bakker; Jack A M Fransen; Petra H M Bovee-Geurts; Frank N van Leeuwen; Niek F Van Hulst; Carl G Figdor
Journal:  J Cell Biol       Date:  2004-01-05       Impact factor: 10.539

View more
  13 in total

1.  The role of genetics in the pathogenesis and diagnosis of type 1 Von Willebrand disease.

Authors:  Veronica H Flood; Jessica Garcia; Sandra L Haberichter
Journal:  Curr Opin Hematol       Date:  2019-09       Impact factor: 3.284

2.  von Willebrand disease and von Willebrand factor.

Authors:  Brooke Sadler; Giancarlo Castaman; James S O'Donnell
Journal:  Haemophilia       Date:  2022-05       Impact factor: 4.263

Review 3.  Prominent Receptors of Liver Sinusoidal Endothelial Cells in Liver Homeostasis and Disease.

Authors:  Ekta Pandey; Aiah S Nour; Edward N Harris
Journal:  Front Physiol       Date:  2020-07-21       Impact factor: 4.566

4.  Nonclinical Safety Assessment of a Long-Acting Recombinant PEGylated Factor Eight (BAY 94-9027) With a 60 kDa PEG.

Authors:  Inge A Ivens; David Banczyk; Katrin Gutberlet; Shawna Jackman; Stéphanie Vauléon; Anna-Lena Frisk
Journal:  Toxicol Pathol       Date:  2019-05-27       Impact factor: 1.902

5.  Removal of Mannose-Ending Glycan at Asn2118 Abrogates FVIII Presentation by Human Monocyte-Derived Dendritic Cells.

Authors:  Sandrine Delignat; Julie Rayes; Suryasarathi Dasgupta; Bagirath Gangadharan; Cécile V Denis; Olivier D Christophe; Jagadeesh Bayry; Srinivas V Kaveri; Sébastien Lacroix-Desmazes
Journal:  Front Immunol       Date:  2020-03-26       Impact factor: 7.561

Review 6.  Role of the Hyaluronan Receptor, Stabilin-2/HARE, in Health and Disease.

Authors:  Edward N Harris; Erika Baker
Journal:  Int J Mol Sci       Date:  2020-05-15       Impact factor: 5.923

Review 7.  Tolerating Factor VIII: Recent Progress.

Authors:  Sebastien Lacroix-Desmazes; Jan Voorberg; David Lillicrap; David W Scott; Kathleen P Pratt
Journal:  Front Immunol       Date:  2020-01-10       Impact factor: 7.561

Review 8.  Biological mechanisms underlying inter-individual variation in factor VIII clearance in haemophilia.

Authors:  Peter L Turecek; Jill M Johnsen; Steven W Pipe; James S O'Donnell
Journal:  Haemophilia       Date:  2020-06-28       Impact factor: 4.287

Review 9.  Hypercoagulability in COVID-19: A review of the potential mechanisms underlying clotting disorders.

Authors:  Walid Alam
Journal:  SAGE Open Med       Date:  2021-03-21

10.  Combination of CLEC4M rs868875 G-Carriership and ABO O Genotypes May Predict Faster Decay of FVIII Infused in Hemophilia A Patients.

Authors:  Barbara Lunghi; Massimo Morfini; Nicola Martinelli; Silvia Linari; Giancarlo Castaman; Francesco Bernardi
Journal:  J Clin Med       Date:  2022-01-29       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.